Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating
Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating
Not thousands of headlines. The few lines that move price. For traders: straight from the source, clear and simple.
Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating
Barclays initiates EU gambling coverage, sees deal synergies driving deleveraging
Kala Bio signs letter of intent to expand genetic testing deal
Uxin surges 12% on narrower loss, upbeat guidance
Brightline Interactive secures $1.25M PIPE financing
The fraudster managed to scam about 100 people across the United States, convincing them of transferring funds to him, claiming their accounts had been hacked.
Your day-ahead look for Sept. 24, 2026
Bybit’s global campaign positions it as a broader financial platform, though its stock, gold and forex derivatives were already available.
U.S. bond yields are little changed early Thursday after yesterday's surge higher sent risk markets sharply lower.
Clocktower’s Eric Wallerstein believes stocks are headed for trouble next year, and safety-seeking investors could drive gold to $6,000 an ounce.
Capital Economics sees fewer ECB rate hikes than markets expect
JPMorgan upgrades CoreWeave on stronger compute pricing
Easing tensions over Taiwan could ripple through the chip stocks powering the AI boom
Whitetip Investments Marks 10 Years of Regulation, Transparency & Responsible Trading
Jaguar Uranium reports rare earth elements at Colombia project
Utility stocks drop on rising rates but valuations look fair - BTIG
BlackRock-backed consortium in talks to buy Stack’s APAC data centers - report
Mizuho reiterates Outperform on Sherwin-Williams stock at $396
Guggenheim raises Travere Therapeutics stock price target on patent
Oppenheimer reiterates Corteva stock rating amid spinoff focus
News text belongs to its source; only the headline and a short summary appear here.